Crispr Historical Balance Sheet

CRSP Stock

USD 47.88 1.59 3.43%

Trend analysis of Crispr Therapeutics AG balance sheet accounts such as Other Current Liab of 30.6 M, Total Current Liabilities of 63.5 M or Total Stockholder Equity of 1 B provides information on Crispr Therapeutics' total assets, liabilities, and equity, which is the actual value of Crispr Therapeutics to its prevalent stockholders. By breaking down trends over time using Crispr Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Crispr Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Crispr Therapeutics is a good buy for the upcoming year.

Crispr Therapeutics Inventory

(9.58 Million)

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crispr Therapeutics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

About Crispr Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Crispr Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Crispr Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Crispr Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Crispr currently owns. An asset can also be divided into two categories, current and non-current.

Crispr Therapeutics Balance Sheet Chart

At this time, Crispr Therapeutics' Other Stockholder Equity is relatively stable compared to the past year. As of 11/25/2024, Accumulated Other Comprehensive Income is likely to grow to about 2 M, while Total Current Liabilities is likely to drop slightly above 63.5 M.

Total Assets Other Current Liab Total Current Liabilities Other Liab Net Tangible Assets Retained Earnings Total Equity

Add Fundamental

Total Assets

Total assets refers to the total amount of Crispr Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Crispr Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Crispr Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Crispr Therapeutics AG are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Retained Earnings Total Equity

The portion of total equity that consists of earnings retained by the company, reinvested in its core business or used to pay debt.

Most accounts from Crispr Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Crispr Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crispr Therapeutics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	79.0M	61.9M	34.9M	30.6M
Total Assets	2.8B	2.2B	2.2B	1.3B

Other Current Liab Total Assets

Crispr Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock
Total Assets		0.94	0.99	1.0	-0.1	0.95	-0.47	-0.73	0.73	0.68	0.9	0.98	0.95	1.0	0.37	0.92	0.94	0.81	0.76	0.93	0.91	0.45	1.0	-0.54	-0.89	0.91
Other Current Liab	0.94		0.93	0.95	-0.2	0.88	-0.52	-0.58	0.58	0.71	0.82	0.94	0.87	0.95	0.18	0.79	0.89	0.72	0.84	0.85	0.83	0.22	0.94	-0.67	-0.78	0.8
Total Current Liabilities	0.99	0.93		0.99	-0.09	0.94	-0.46	-0.77	0.75	0.67	0.9	0.97	0.94	0.99	0.37	0.93	0.94	0.81	0.78	0.94	0.92	0.45	0.99	-0.54	-0.91	0.93
Total Stockholder Equity	1.0	0.95	0.99		-0.13	0.95	-0.5	-0.72	0.71	0.7	0.88	0.98	0.95	1.0	0.36	0.91	0.94	0.78	0.76	0.93	0.89	0.44	1.0	-0.56	-0.89	0.91
Other Liab	-0.1	-0.2	-0.09	-0.13		-0.16	-0.21	0.11	-0.13	0.14	-0.18	-0.07	-0.11	-0.09	-0.16	0.14	-0.21	0.24	-0.07	-0.15	0.13	-0.08	-0.09	0.42	-0.03	0.15
Net Tangible Assets	0.95	0.88	0.94	0.95	-0.16		-0.4	-0.84	0.86	0.66	0.94	0.92	0.99	0.94	0.59	0.88	0.91	0.76	0.71	0.99	0.86	0.61	0.95	-0.56	-0.95	0.88
Net Debt	-0.47	-0.52	-0.46	-0.5	-0.21	-0.4		0.13	0.0	-0.95	-0.12	-0.55	-0.44	-0.53	0.16	-0.57	-0.43	-0.12	-0.52	-0.36	-0.25	0.08	-0.51	0.56	0.4	-0.59
Retained Earnings	-0.73	-0.58	-0.77	-0.72	0.11	-0.84	0.13		-0.95	-0.39	-0.84	-0.67	-0.82	-0.7	-0.77	-0.78	-0.77	-0.66	-0.53	-0.9	-0.73	-0.77	-0.72	0.39	0.91	-0.77
Accounts Payable	0.73	0.58	0.75	0.71	-0.13	0.86	0.0	-0.95		0.31	0.91	0.64	0.83	0.69	0.86	0.71	0.72	0.73	0.5	0.9	0.77	0.84	0.71	-0.33	-0.89	0.71
Cash	0.68	0.71	0.67	0.7	0.14	0.66	-0.95	-0.39	0.31		0.41	0.74	0.69	0.73	0.09	0.74	0.64	0.36	0.67	0.63	0.49	0.15	0.72	-0.66	-0.65	0.76
Non Current Assets Total	0.9	0.82	0.9	0.88	-0.18	0.94	-0.12	-0.84	0.91	0.41		0.84	0.91	0.87	0.6	0.79	0.86	0.83	0.69	0.95	0.9	0.6	0.88	-0.42	-0.91	0.8
Non Currrent Assets Other	0.98	0.94	0.97	0.98	-0.07	0.92	-0.55	-0.67	0.64	0.74	0.84		0.95	0.99	0.27	0.89	0.9	0.74	0.71	0.9	0.85	0.34	0.98	-0.5	-0.85	0.9
Other Assets	0.95	0.87	0.94	0.95	-0.11	0.99	-0.44	-0.82	0.83	0.69	0.91	0.95		0.95	0.55	0.88	0.89	0.75	0.66	0.98	0.85	0.57	0.95	-0.5	-0.94	0.89
Cash And Short Term Investments	1.0	0.95	0.99	1.0	-0.09	0.94	-0.53	-0.7	0.69	0.73	0.87	0.99	0.95		0.33	0.91	0.93	0.79	0.77	0.92	0.9	0.4	1.0	-0.56	-0.88	0.91
Net Receivables	0.37	0.18	0.37	0.36	-0.16	0.59	0.16	-0.77	0.86	0.09	0.6	0.27	0.55	0.33		0.4	0.4	0.42	0.12	0.62	0.43	0.96	0.36	-0.18	-0.63	0.38
Common Stock Total Equity	0.92	0.79	0.93	0.91	0.14	0.88	-0.57	-0.78	0.71	0.74	0.79	0.89	0.88	0.91	0.4		0.88	0.74	0.76	0.88	0.84	0.5	0.92	-0.46	-0.93	1.0
Common Stock Shares Outstanding	0.94	0.89	0.94	0.94	-0.21	0.91	-0.43	-0.77	0.72	0.64	0.86	0.9	0.89	0.93	0.4	0.88		0.73	0.79	0.91	0.84	0.48	0.94	-0.69	-0.89	0.88
Non Current Liabilities Total	0.81	0.72	0.81	0.78	0.24	0.76	-0.12	-0.66	0.73	0.36	0.83	0.74	0.75	0.79	0.42	0.74	0.73		0.58	0.76	0.98	0.51	0.8	-0.23	-0.78	0.73
Other Current Assets	0.76	0.84	0.78	0.76	-0.07	0.71	-0.52	-0.53	0.5	0.67	0.69	0.71	0.66	0.77	0.12	0.76	0.79	0.58		0.71	0.68	0.15	0.76	-0.74	-0.74	0.78
Other Stockholder Equity	0.93	0.85	0.94	0.93	-0.15	0.99	-0.36	-0.9	0.9	0.63	0.95	0.9	0.98	0.92	0.62	0.88	0.91	0.76	0.71		0.86	0.63	0.93	-0.54	-0.97	0.89
Total Liab	0.91	0.83	0.92	0.89	0.13	0.86	-0.25	-0.73	0.77	0.49	0.9	0.85	0.85	0.9	0.43	0.84	0.84	0.98	0.68	0.86		0.51	0.9	-0.35	-0.86	0.83
Short Long Term Debt	0.45	0.22	0.45	0.44	-0.08	0.61	0.08	-0.77	0.84	0.15	0.6	0.34	0.57	0.4	0.96	0.5	0.48	0.51	0.15	0.63	0.51		0.44	-0.18	-0.66	0.47
Total Current Assets	1.0	0.94	0.99	1.0	-0.09	0.95	-0.51	-0.72	0.71	0.72	0.88	0.98	0.95	1.0	0.36	0.92	0.94	0.8	0.76	0.93	0.9	0.44		-0.56	-0.89	0.92
Short Term Debt	-0.54	-0.67	-0.54	-0.56	0.42	-0.56	0.56	0.39	-0.33	-0.66	-0.42	-0.5	-0.5	-0.56	-0.18	-0.46	-0.69	-0.23	-0.74	-0.54	-0.35	-0.18	-0.56		0.52	-0.48
Intangible Assets	-0.89	-0.78	-0.91	-0.89	-0.03	-0.95	0.4	0.91	-0.89	-0.65	-0.91	-0.85	-0.94	-0.88	-0.63	-0.93	-0.89	-0.78	-0.74	-0.97	-0.86	-0.66	-0.89	0.52		-0.94
Common Stock	0.91	0.8	0.93	0.91	0.15	0.88	-0.59	-0.77	0.71	0.76	0.8	0.9	0.89	0.91	0.38	1.0	0.88	0.73	0.78	0.89	0.83	0.47	0.92	-0.48	-0.94

Click cells to compare fundamentals

Crispr Therapeutics Account Relationship Matchups

Crispr Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.1B	1.8B	2.8B	2.2B	2.2B	1.3B
Other Current Liab	41.7M	49.6M	79.0M	61.9M	34.9M	30.6M
Total Current Liabilities	57.1M	94.3M	119.9M	121.1M	108.8M	63.5M
Total Stockholder Equity	939.4M	1.7B	2.4B	1.9B	1.9B	1.0B
Other Liab	26.2M	19.4M	19.7M	18.3M	16.5M	15.6M
Net Tangible Assets	939.2M	1.7B	2.4B	1.9B	2.2B	2.3B
Net Debt	(891.2M)	(1.1B)	(698.0M)	32.1M	(150.8M)	(158.4M)
Retained Earnings	(224.7M)	(573.6M)	(195.9M)	(846.1M)	(999.7M)	(949.7M)
Accounts Payable	5.9M	9.1M	14.8M	27.4M	38.1M	40.1M
Cash	943.8M	1.2B	923.0M	211.9M	389.5M	528.6M
Non Current Assets Total	79.2M	111.3M	334.4M	390.0M	321.5M	337.6M
Non Currrent Assets Other	6.1M	18.1M	22.2M	16.3M	13.6M	9.7M
Other Assets	6.1M	18.1M	22.2M	16.3M	18.7M	19.7M
Cash And Short Term Investments	943.8M	1.7B	2.4B	1.8B	1.7B	1.1B
Net Receivables	99K	144K	305K	11.2M	200M	210M
Common Stock Total Equity	1.8M	2.3M	2.4M	2.4M	2.8M	1.6M
Common Stock Shares Outstanding	56.9M	65.9M	80.4M	77.7M	79.2M	57.1M
Liabilities And Stockholders Equity	1.1B	1.8B	2.8B	2.2B	2.2B	1.3B
Non Current Liabilities Total	70.2M	69.5M	232.5M	246.5M	238.0M	139.7M
Other Current Assets	43.7M	15.4M	29.7M	37.7M	14.4M	17.4M
Other Stockholder Equity	1.2B	2.2B	2.6B	2.7B	2.9B	3.0B
Total Liab	127.3M	163.7M	352.4M	367.6M	346.8M	203.2M
Total Current Assets	987.5M	1.7B	2.4B	1.9B	1.9B	1.1B
Accumulated Other Comprehensive Income	7K	(83K)	(5.1M)	(15.6M)	1.9M	2.0M
Short Term Debt	8.5M	22.7M	24.3M	31.7M	31.3M	26.8M
Intangible Assets	235K	180K	125K	71K	16K	15.2K
Common Stock	1.8M	2.3M	2.4M	2.4M	2.5M	1.7M
Property Plant And Equipment Net	72.8M	93.0M	312.0M	320.6M	305.9M	321.2M
Capital Surpluse	1.2B	2.2B	2.6B	2.7B	3.1B	3.3B
Property Plant And Equipment Gross	72.8M	93.0M	137.6M	163.6M	359.4M	377.3M
Property Plant Equipment	72.8M	42.2M	137.6M	163.6M	188.2M	197.6M
Current Deferred Revenue	960K	2.3M	1.0M	12.3M	4.1M	3.9M
Retained Earnings Total Equity	(224.7M)	(573.6M)	(195.9M)	(846.1M)	(761.5M)	(723.4M)
Non Current Liabilities Other	14.4M	69.5M	232.5M	6.0M	958K	910.1K
Net Invested Capital	939.4M	1.7B	2.4B	1.9B	1.9B	1.5B

Pair Trading with Crispr Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Crispr Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Crispr Stock

0.53	MTEM	Molecular Templates	Pair Corr
0.35	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.32	TCHH	Trustcash Holdings	Pair Corr
0.31	ME	23Andme Holding	Pair Corr

The ability to find closely correlated positions to Crispr Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Crispr Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Crispr Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Crispr Therapeutics AG to buy it.

The correlation of Crispr Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Crispr Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Crispr Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Crispr Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Crispr Stock Analysis

When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Crispr Historical Balance Sheet

Crispr Therapeutics Inventory

(9.58 Million)

About Crispr Balance Sheet Analysis

Crispr Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Net Tangible Assets

Retained Earnings Total Equity

Crispr Therapeutics balance sheet Correlations

Crispr Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Crispr Therapeutics balance sheet Accounts

Pair Trading with Crispr Therapeutics

Moving against Crispr Stock

Additional Tools for Crispr Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments

Intangible Assets	- 0.97	Other Stockholder Equity
Accounts Payable	- 0.95	Retained Earnings
Cash	- 0.95	Net Debt
Intangible Assets	- 0.95	Net Tangible Assets
Common Stock	- 0.94	Intangible Assets
Intangible Assets	- 0.94	Other Assets